Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: Favorable results in acute and chronic myeloid leukemia

Cytotherapy

Volumn 6, Issue 6, 2004, Pages 533-542

  Kobbe, Guido ^a   Fenk, R ^a   Neumann, F ^a   Bernhardt, A ^a   Steidl, U ^a   Kondakci, M ^a   Graef, T ^a   Aivado, M ^a   Vaupel, M ^a   Huenerlituerkoglu, A N ^a   Kronenwett, R ^a   Pape, H ^a   Hildebrand, B ^a   Germing, U ^a   Haas, R ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

CD34 selection; Unrelated donor transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GANCICLOVIR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SANDIMMUN OPTORAL; TACROLIMUS; THIOTEPA; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSPLANTATION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OPPORTUNISTIC INFECTION; PROGNOSIS; SIBLING; STATISTICAL ANALYSIS; SURVIVAL RATE; T LYMPHOCYTE;

EID: 19944418258     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410005375     Document Type: Article

References (62)

1. Hansen JA, Clift RA, Thomas ED et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565-7.
2. Sierra J, Storer B, Hansen JA et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397-404.
3. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993;81:543-50.
4. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572-7.
5. Champlin RE, Passweg JR, Zhang MJ et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000;95:3996-4003.
6. Alyea EP, Weller E, Fisher DC et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002;8:601-7.
7. Bunjes D. 188Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia. Leuk Lymphoma 2002;43:2125-31.
8. Hale G, Waldmann H. Risks of developing Epstein - Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998;91:3079-83.
9. +- enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002;118:1095-103.
10. Bunjes D. The current status of T-cell depleted allogeneic stem-cell transplants in adult patients with AML. Cytotherapy 2001;3:175-88.
11. Baron F, Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002;8:351-9.
12. Porter DL, Collins RH Jr, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-21.
13. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
14. + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003;101:446-53.
15. Ottinger HD, Muller CR, Goldmann SF et al. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 2001;80:706-14.
16. Fritsch G, Scharner D, Froschl G et al. Selection of CD34-positive blood cells for allogeneic transplantation: approaches to optimize D34-cell recovery, purity, viability, and T-cell depletion. Onkologie 2000;23:449-56.
17. O'Donnell PV, Myers B, Edwards J et al. CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts. Cytotherapy 2001;3:483-8.
18. Neumann F, Herold C, Hildebrandt B et al. Quantitative realtime reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003;70:1-10.
19. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-8.
20. Kobbe G, Schneider P, Rohr U et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001;28:47-9.
21. Ferra C, Rodriguez-Luaces M, Gallardo D et al. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:963-8.
22. + selected cells from peripheral blood. Blood 1997;89:3967-73.
23. + cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish group of allo-PBT. Bone Marrow Transplant 1998;22:519-25.
24. Roberts MM, Dyson P, Rawling C et al. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. Cytotherapy 2003; 5:534-41.
25. + cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. J Hematother Stem Cell Res 2003;12:309-20.
26. + selected PBPC grafts unselected PBPC grafts or BM grafts. Bone Marrow Transplant 1999;24:295-302.
27. Storek J, Storb R. T-cell reconstitution after stem-cell transplantation: by which organ. Lancet 2000;355:1843-14.
28. Fallen PR, McGreavey L, Madrigal JA et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003;32:1001-14.
29. Verfuerth S, Peggs K, Vyas P et al. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 2000;95:3990-5.
30. + cells in three children with refractory severe aplastic anemia. Bone Marrow Transplant 2000;25:513-7.
31. + progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation. Ann NY Acad Sci 1999;872:336-48.
32. Rebello P, Cwynarski K, Varughese M et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001;3:261-7.
33. Bunn D, Lea CK, Bevan DJ et al. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996;45:29-32.
34. Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003;102:404-6.
35. Solomon SR, Nakamura R, Read EJ et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:783-8.
36. Pihusch R, Holler E, Muhlbayer D et al. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:347-54
37. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990;75:1011-6.
38. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002;100:397-405.
39. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
40. Chakrabarti S, Milligan DW, Pillay D et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003;102:839-42.
41. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001;72:1460-3.
42. Hertenstein B, Hampl W, Bunjes D et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995;15:387-93.
43. Regn S, Raffegerst S, Chen X et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 2001;27:53-64.
44. Einsele H, Bertz H, Beyer J et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82 Suppl 2:S175-85.
45. Chakrabarti S, Mackinnon S, Chopra R et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99:4357-63.
46. Chakrabarti S, Osman H, Collingham K, Milligan DW. Polymna viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning. Bone Marrow Transplant 2003; 31:379-86.
47. Chakrabarti S, Mautner V, Osman H et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002;100:1619-27.
48. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002;30:495-501.
49. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-9.
50. Vasconcelos ZF, Diamond HR, Tabak DG, Barcinski MA, Bonomo A. Th1/Th2 lymphokine profile of T cells present in the blood of granulocyte-colony stimulating factor-treated stem-cell donors: up or down modulation. Blood 2001;97:333-5.
51. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-90.
52. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-80.
53. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002;8:625-32.
54. Baron F, Frere P, Baudoux E et al. Low incidence of acute graft-versus-host disease after non-myeloablative stem cell transplantation with CD8-depleted peripheral blood stem cells: an update. Haematologica 2003;88:835-7.
55. Baron F, Siquet J, Schaaf-Lafontaine N et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 2002;87:78-88.
56. Azuma E, Hirayama M, Yamamoto H, Komada Y. The role of donor age in naive T-cell recovery following allogeneic hematopoietic stem cell transplantation: the younger the better. Leuk Lymphoma 2002;43:735-9.
57. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80.
58. Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000;69:1341-7.
59. Storek J, Dawson MA, Storer B et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-9.
60. Morecki S, Gelfand Y, Nagler A et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9.
61. + donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002;8:2052-60.
62. + T cells do not induce graft-versus-host disease. J Clin Invest 2003;112: 101-8.